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SUMMARY: Metallo-b-lactamase (MBL)-producing Acinetobacter baumannii has become a growing
therapeutic concern worldwide. The aims of this study were to evaluate the antimicrobial susceptibility
of A. baumannii isolates and to determine the prevalence of MBL genes among carbapenem non-
susceptible isolates. During a period of 16 months (March 2008June 2009), 100 isolates of A. bauman-
nii were collected from different clinical specimens of inpatients admitted to the largest teaching
hospital in the northwest of Iran. All isolates were tested for antimicrobial susceptibility by Kirby-Bauer
disk diffusion method. Carbapenem non-susceptible isolates were further screened for production of
MBL by Etest and were then subjected to PCR for detection of MBL genes of types blaIMP and blaVIM.
Among 63 carbapenem (imipenem and meropenem) non-susceptible isolates of A. baumannii, 31 (49z)
were found to be MBL producers. Of 31 MBL-producing isolates, 19 (61z) carried the blaIMP gene and
9 (29z) carried the blaVIM gene. All MBL-producing isolates were multidrug resistant. This is the first
report of IMP and VIM types among MBL-producing A. baumannii in Iran.
Acinetobacter baumannii is a significant opportunis-
tic pathogen. It is widely distributed in the hospital en-
vironment and causes a wide range of infections, partic-
ularly respiratory tract infections, urinary tract infec-
tions, meningitis, septicemia, and wound infections (1).
Antimicrobial treatment of nosocomial infection caused
by A. baumannii is often difficult due to the multidrug-
resistant (MDR) nature of this organism. The scope of
MDR was defined as those isolates that are resistant to
more than two different classes of the antimicrobial
agents that include cephalosporins, carbapenems,
aminoglycosides, fluoroquinolones, and ampicillin-
sulbactam. Carbapenems are usually the drug of choice
for treatment of infections caused by MDR A. bauman-
nii (2). In recent years, some outbreaks of carbapenem-
resistant A. baumannii have been reported from differ-
ent parts of the world (35). Carbapenem-hydrolyzing
metallo-b-lactamases (MBLs) belong to class B b-lac-
tamases which can hydrolyze all b-lactams except
monobactams. The IMP and VIM are the most preva-
lent types of acquired MBLs (6). Nowadays, the MBL-
producing A. baumannii is a major concern to clini-
cians. There have as yet been no reports concerning the
MBL-producing A. baumannii in Iran. The aims of this
study were (i) to access the antimicrobial susceptibility
of A. baumannii isolated from Imam Reza hospital in
Tabriz and (ii) to determine the prevalence of MBL
genes among carbapenem non-susceptible isolates.
This study was carried out at a 1,000-bed tertiary-care
hospital in Tabriz, Iran, the largest teaching hospital in
the northwest of Iran. One hundred non-duplicated
clinical isolates were collected during a period of 16
months between March 2008 and June 2009 from
patients admitted to the hospital. The isolates were iden-
tified using standard laboratory methods (5) and then
confirmed by detection of blaOXA-51-like carbapenemase
genes as described previously (7). A total of 100 A. bau-
mannii isolates were obtained from different clinical
specimens, including tracheal aspirate (37z), urine
(21z), sputum (9z), blood (7z), catheter (6z), bron-
chial washings (6z), wounds (5z), abscess drainage
(3z), cerebrospinal fluid (2z), ascites (2z), and
pleural effusion (2z). Seventy-two patients (72z) were
males and 28 (28z) were females. Their ages ranged
from 14 to 86 years with a median of 52 years. The iso-
lates were cultured from patients in intensive care units
(38z) and internal medicine (24z), neurosurgery
(17z), infectious disease (9z), neurology (8z), and
general surgery (3z) wards. Antimicrobial susceptibil-
ity of all isolates was determined using the standard
Kirby-Bauer disk diffusion method according to Clini-
cal and Laboratory Standards Institute (CLSI) guide-
lines (8). The antimicrobial agents tested were ampicil-
lin-sulbactam (10/10 mg), piperacillin-tazobactam
(100/10 mg), amoxicillin/clavulanic acid (20/10 mg),
ticarcillin/clavulanic acid (75/10 mg) , ceftriaxone (30
mg), cefepime (30 mg), ceftazidime (30 mg), piperacillin
(100 mg), aztreonam (30 mg), imipenem (10 mg),
meropenem (10 mg), gentamicin (10 mg), ciprofloxacin
(5 mg), levofloxacin (5 mg), amikacin (30 mg), and
trimethoprim/sulfamethoxazole (25 mg). All an-
timicrobials were purchased from Mast, Merseyside,
UK. Pseudomonas aeruginosa ATCC 27853 was used as
the control strain in susceptibility testing. The isolates
